This attachment to a government file provides a comprehensive list of 25 pediatric vaccines, outlining key details for each. For every vaccine, the document specifies the minimum shelf life of 12 months, applicable federal excise tax per dose (if any), and the maximum and minimum number of doses required. The delivery date and location for all vaccines are designated as "TBD" and "To be shown on Delivery Orders," respectively. The list includes a wide range of vaccines such as Dengue, DTaP combinations, Hepatitis A and B (pediatric and adult), Hib, Human Papillomavirus, Measles Mumps & Rubella (MMR), Meningococcal variants, Mpox, Pneumococcal Conjugate, Respiratory Syncytial Virus, Rotavirus, Tetanus and Diphtheria (Td), Tdap, and Varicella. This document serves as a detailed procurement guide, essential for federal, state, or local RFP processes related to vaccine supply.

The Authorized Distributor of Record (ADR) Agreement establishes a relationship between a manufacturer/supplier and the Centers for Disease Control and Prevention (CDC), designating the CDC as an ADR as per the Prescription Drug Marketing Act (PDMA) of 1988 and 21 CFR Part 203. The CDC agrees to comply with all applicable state and federal laws to maintain this status. Manufacturers must provide a list of specific products the CDC is authorized to distribute, identified by pharmaceutical/vaccine name, dosage form, strength, and NDC number, or state that the CDC is an ADR for their entire product line. This agreement is valid from dual execution until terminated by either party with ninety days' written notice, and it does not alter any other existing or future distribution agreements. It serves solely to designate the CDC as an ADR, not as a sales agreement. The document includes signature lines for both the CDC's U.S. Government Contracting Officer and the Manufacturer/Supplier, along with an optional Attachment A-1 for listing specific products.

Attachment 03, titled "List of Products," is a document outlining a concise list of three vaccine products. Each entry includes an "Item No.," the "Product/Brand Name" (consistently listed as "Vaccine"), and a corresponding "NDC" (National Drug Code) number. The repeated listing of "Vaccine" for each item suggests a focus on these specific products for procurement, distribution, or regulatory purposes. This attachment likely serves as a reference within a larger government document, such as an RFP or grant application, to specify the exact vaccine products being addressed or requested.

This government file outlines an Indefinite Delivery Indefinite Quantity (IDIQ) contract for the procurement and distribution of pediatric vaccines by the Centers for Disease Control and Prevention (CDC). The Vaccines for Children (VFC) program, established under OBRA '93, ensures federal support for vaccine purchases for eligible children (18 and younger) who are Medicaid-eligible, uninsured, American Indian/Alaska native, or those with insurance that doesn't cover vaccines and receive immunizations at specific health centers. The contract, with a period of performance from April 1, 2026, to March 31, 2027, specifies firm-fixed-price delivery orders. It details contract clauses covering shelf life, packaging, delivery times (15 working days), places of delivery (CDC centralized locations), product licensure (FDA, CGMPR's), and ordering procedures via the Vaccine Tracking System (VTrckS). Fair opportunity for orders is based on clinical appropriateness, state medical advisory recommendations, and funding. The maximum value for all contracts is over $13 billion. Key provisions include restrictions on vaccine use (only for eligible children, no resale or free distribution outside immunization programs), federal excise tax credit procedures, and requirements for delinquent delivery and biological surveillance data reports. Contractors are prohibited from offering inducements and must provide advance notice of supply issues. The document also includes a vaccine order limitation chart listing various pediatric vaccines with minimum and maximum dose quantities.

The Centers for Disease Control and Prevention (CDC) has issued a solicitation for an Indefinite Delivery Indefinite Quantity (IDIQ) contract for pediatric vaccines, under the Vaccines for Children (VFC) program. This initiative aims to procure a wide range of vaccines, including DTaP, Hepatitis A and B, MMR, Meningococcal, Pneumococcal, and Rotavirus, to cover eligible children aged 18 and younger. The contract, with a period of performance from April 1, 2026, to March 31, 2027, has a combined maximum value of over $13 billion for all awarded contracts. Key requirements include a minimum 12-month shelf life upon delivery, specific packaging and packing standards, and adherence to FDA product licensure and Good Manufacturing Practices. Ordering will primarily occur through the Vaccine Tracking System (VTrckS), with strict guidelines on order placement, delivery timelines (within 15 working days), and limitations on minimum and maximum order quantities. The contractor must also provide advance notice of supply issues and adhere to prohibitions on inducements to providers. The CDC emphasizes fair opportunity in order placement, considering clinical appropriateness, state-level recommendations, and funding availability. The contract also incorporates various Federal Acquisition Regulation (FAR) and Health and Human Services Acquisition Regulation (HHSAR) clauses.

This government solicitation, 75D301-26-R-73375, outlines an Indefinite Delivery Indefinite Quantity (IDIQ) contract for pediatric vaccines under the Vaccines for Children (VFC) program, managed by the Centers for Disease Control and Prevention (CDC). The contract aims to secure standard commercial pediatric vaccines for eligible children aged 18 and younger, including those who are Medicaid-eligible, uninsured, American Indian/Alaska Native, or insured but receiving immunizations at federally-qualified health centers. The contract period is from April 1, 2026, to March 31, 2027, with a combined maximum value of over $13 billion for all contracts. Manufacturers must provide FDA-licensed vaccines with a minimum 12-month shelf life upon delivery, adhering to strict packaging, packing, and temperature monitoring requirements. Orders will be placed electronically via the Vaccine Tracking System (VTrckS), with specific clauses detailing delivery times, order limitations (minimum 100 doses for most vaccines), payment methods, and prohibitions on inducements. The document also includes numerous FAR and HHSAR clauses, emphasizing compliance, contractor performance evaluation through CPARS, and information and communication technology accessibility.

This government solicitation, RFP number 75D301-26-R-73375, issued by the Centers for Disease Control and Prevention (CDC), outlines an Indefinite Delivery Indefinite Quantity contract for pediatric vaccines under the Vaccines for Children (VFC) program. The program ensures federal support for vaccine purchases for eligible children. The contract, effective from April 1, 2026, to March 31, 2027, has a maximum combined value of over $13 billion and covers a wide range of vaccines, including DTaP, Hepatitis, MMR, HPV, and Pneumococcal. Key clauses detail shelf life, packaging, delivery within 15 working days, product licensure, electronic ordering via VTrckS, and limitations on order size. Contractors must comply with FDA regulations, provide product information, and report supply issues. The CDC is designated as an Authorized Distributor of Record for all distributed vaccines.

This document is a Standard Form 1449,